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Available online 28 May 2013The purpose of this study was to design a novel in vitro tool by using recombinant protein
technology to detect specific antibody responses against Toxoplasma gondii in a simple, rapid and
highly sensitive reagent. The surface T. gondii SAG1 protein is an important immunodominant
target, which provides a great interest as a diagnostic antigen. To further exploit its immuno-
detection capacity, in the present study, the full length sag1 gene was inserted into the pLIP6
prokaryotic expression vector so as to produce a SAG1 antigen genetically fused to the bacterial
alkaline phosphatase (AP). After expression optimization, the recombinant fusion protein folded
correctly in soluble form in the periplasmic space and preserved both the AP enzymatic activity
and the SAG1 immunoreactivity. Subsequently, direct-ELISA and dot-blot immunoassays were
designed, using crude preparation SAG1–AP conjugate, to explore its value in serodiagnosis of
human toxoplasmosis. We demonstrate that the recombinant SAG1–AP can detect specific
T. gondii antibodies in one-step procedure and can successfully discriminate between T. gondii
immune and non-immune patients, in agreement with the standard gold test. In conclusion, the
present study shows that the genetic fusion protein provides a new tool for one-step T. gondii
immunodetection, which was easily, quickly and reproducibly produced as homogeneous
bi-functional reagent. Thus, this recombinant immunoconjugate is a promising marker for
Toxoplasma serodiagnosis, requiring further evaluation on a larger series and could provide the
basis for direct antibody capture enzyme-immunoassay for specific immunoglobulin M and G
detection.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.Keywords:
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Immunoenzymatic conjugates1. Introduction
Toxoplasma gondii (T. gondii) is an intracellular protozoan
parasite that infects a large variety of domestic and wildsurface antigen-1; AP,
side; PBS, phosphate-
5-bromo-4-choro-1-
poly-acrylamide gel
t assay
: +216 71 791 833.
M. Mousli).
r B.V. Open access under CC BYmammals, including humans. In humans, infection with
T. gondii is generally asymptomatic but during pregnancy, it
can result in congenital infection with severe sequelae or late
onset eye disease and is a frequent cause of encephalitis in
severely immune suppressed patients with AIDS (Araujo and
Remington, 1987). Toxoplasmosis is also a serious complica-
tion following organ transplantation (Aubert et al., 1996).
So, detection of T. gondii infection by sensitive and specific
methods is a key step towards treating and managing patients
with suspected toxoplasmosis. Serological assays are the initial
and primary tests routinely used for toxoplasmosis diagnosis
(Montoya, 2002).Most of the commercially available kits detect
specific anti-Toxoplasma immunoglobulins by means of native
antigens originating from T. gondii. The main disadvantage license.
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serology tests is its inconstant quality. The use of recombinant
proteins obtained viamolecular biology is an alternative for the
detection of serumantibodies that allowbetter standardization
of the immunoassays and may enhance the sensitivity of an
antibody-based assay (see review, Kotresha and Noordin,
2010). Besides, current detecting methods using enzyme-
labeled conjugates present several advantages such as, stability,
safety of the reagents, intrinsic amplification, and the various
methods available to measure enzyme activity (Guesdon,
1992). However, the immunoconjugates are obtained by
chemical labeling, which present different drawbacks, such as
a random cross-linking chemical reaction, partial denaturation
of both components and heterogeneity of coupling (non-
uniform antibody or antigen/enzyme stoichiometries)
(Porstmann and Kiessig, 1992; Avrameas, 1983). To overcome
these problems, while preserving the advantage of using
enzyme-linked proteins, gene fusion technology which allows
direct production of enzyme tagged recombinant proteins in a
bacterial expression system (Lindbladh et al., 1993) might
constitute an interesting approach. Escherichia coli (E. coli)
alkaline phosphatase (EC 3.1.3.1) (AP) which displays sub-
strate specificity similar to the calf intestinal enzyme was
efficiently expressed in E. coli when coupled at its amino
terminus to different antibody fragments (Carrier et al., 1995;
Muller et al., 1999; Mousli et al., 2007) or antigens (Gillet et al.,
1993; Chanussot et al., 1996; Butera et al., 2003)without loss of
activity. In addition, AP and AP-fusions are secreted into the
bacterial periplasm (Michaelis et al., 1983); thus, disulfide
bonds required for target proteins can be formed and fusion
proteins readily extracted from bacteria by periplasmic lysis
using cold osmotic shock. Finally, multiple chromogenic and
fluorogenic substrates exist, allowing direct quantification of
the amount of fusion protein bound to a target protein with
high sensitivity (Brickman and Beckwith, 1975). Thus, recom-
binant tracers constitute an alternative way of providing
homogeneous and stable immunoconjugates for use in diag-
nostic assays.
The surface antigen 1 (SAG1, also named P30) is the major
T. gondii component being expressed on the surface of intra-
and extra cellular tachyzoïtes (Dubremetz et al., 1985) and
was suggested to be themost immunogenic constituent of the
invasive form (Rodriguez et al., 1985). It is a non-variant
antigen which is well conserved immunologically and in
amino acid sequence levels (Nagel and Boothroyd, 1989).
T. gondii SAG1 gene has been expressed in various heterolo-
gous systems and the recombinant antigen was widely used
in Toxoplasma serodiagnosis (Kotresha and Noordin, 2010).
Recently, we have demonstrated that the recombinant SAG1
antigen, produced in bacterial system, shows a high capacity
to screen anti-Toxoplasma IgG antibodies in sera as well as in
saliva samples from pregnant women using ELISA system
(Chahed Bel-Ochi et al., 2013). In the present study, to further
exploit its immunodetection capacity, we proposed to design
a recombinant SAG1 protein genetically fused to E. coli
alkaline phosphatase for use in rapid, sensitive and specific
Toxoplasma serodiagnosis tests. After bacterial expression
optimization, the bi-functionality of the SAG1–AP immuno-
conjugate was characterized, and then it was applied in
one-step detection immunoassays such as direct-ELISA and
dot-immunoblotting for Toxoplasma serodiagnosis.2. Materials and methods
2.1. Bacterial strains and plasmids
The E. coli DH5α strain (Invitrogen, Carlsbad, CA) was
used for the preparation of plasmids and cloning. The E. coli
XL1-Blue (Stratagene, La Jolla, USA) and W3110 strains
(American Type Culture Collection, no. 27325) were applied to
the expression of recombinant fused antigen.
The pLIP6-GN vector was kindly provided by Dr Ducancel
F. (Laboratoire d'Ingénierie des Anticorps pour la Santé
CEA-Saclay, France). This vector presents a SfiI/NotI cloning
site between codons coding for residues +6 and +7 of
mature alkaline phosphatase. In the empty pLIP6-GN vector,
the AP gene is out of frame and advantageously restored
upon cloning of the foreign DNA insert, permitting a visual
selection of blue cloned colonies on BCIP agar plates (Gillet et
al., 1992). The presence of both the signal peptide and the
first six amino acid residues of AP facilitate export of the
hybrid into the periplasmic space of E. coli, after induction of
the tac promoter with IPTG.
2.2. Construction of sag1–AP fusion gene expression vector
The DNA sequence of the gene encoding the T. gondii
SAG1 antigen was obtained from the GenBank (accession no.
X14080). The entire sag1 gene was amplified by PCR from the
pET22-sag1-His plasmid (Chahed Bel-Ochi et al., 2013) with
the following primers: P1: 5′-GTCCTCGCAACTGCGGCCCAGC
CGGCCATGGCATCGGATCCCCCTCTTGTTG-3′ and P2: 5′-ATGA
TGTGCGGCCGCCGCGACACAAGCTGCCG-3′, which introduced
the underlined SfiI and NotI recognition sites at the 5′ and 3′
ends of the PCR product, respectively. The bold text within
the primer sequences indicates complementarity to the
nucleotide sequences of the sag1 gene, whereas 5′ overhang-
ing ends of primers were designed to facilitate cloning.
Specific 867 bp PCR product was digested with SfiI and
NotI restriction enzymes (Amersham Biosciences, France)
and then, isolated from an agarose gel band using GFX PCR
DNA and Gel Band Purification Kit (Amersham Biosciences,
France). This DNA fragment was ligated into pLIP6-GN vector
previously linearized with the same enzymes and used to
transform E. coli DH5α strain. The transformed bacteria were
seeded in Luria-Bertani (LB)-Agar plates, containing 100 μg/ml
ampicillin, 100 μM IPTG (Isopropylthio-β-galactoside, Sigma-
Aldrich, Inc., Germany), and 40 mg/ml BCIP (5-Bromo-4-
chloro-3′-indolyphosphate, Sigma-Aldrich, Inc., Germany).
The phosphate in the media inhibits the expression of the
constitutive DH5α AP gene, while the IPTG induces the tac
promoter, allowing the expression of AP fusion proteins that
hydrolyses the BCIP substrate resulting in blue colonies
(Boulain and Ducancel, 2004). Three independently positive
ampicillin-resistant blue colonies containing sag1 gene frag-
ment were selected and analyzed by sequencing using the ABI
PRISM Cycle Sequencing kit (ABI, Applied Biosystems).
2.3. E. coli cultures and fusion protein expression
A single clone pLIP6-sag1–AP was used to transform fresh
competent E. coli XL-Blue and W3110 strains (Sambrook and
Russel, 2001). Colonieswere grown in LBmediumsupplemented
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approximately 0.6 to 0.8. The tac promoter was then induced
with IPTG and the culture temperature was shifted to 28 °C for
16 h with shaking at 200 rpm. To optimize the production of
SAG1–AP fusion protein, a range of IPTG concentrations was
used (0.1–1 mM) and cultures were incubated under the same
conditions.
Extracts containing periplasmic fusion protein were
prepared from pelleted bacteria after a modified cold osmotic
shock as previously described (Skerra and Pluckthun, 1988).
Briefly, the biomass obtained from 1 l bacterial culture was
suspended in 100 ml TES hypertonic solution (300 mM Tris–
HCl, pH 8, 1 mM EDTA, 20% sucrose) containing 10 μg/mL
lysosyme. After 10 min incubation on ice, the soluble periplas-
mic fraction was collected by centrifugation at 7000 g for
30 min at 4 °C. Fractions containing the recombinant SAG1–AP
were dialyzed against PBS (Phosphate Buffered Saline) and a
protease inhibitor cocktail (Roche Applied Science) was added
before storing at−20 °C till use.2.4. Expression analysis
The presence and the integrity of the recombinant fusion
protein were checked using 10% SDS-PAGE gel and silver-
staining. Two Western blots were performed to reveal the
fusion protein bands, the first under reducing condition with
anti-bacterial APMAb (ProductNo. B-6804, Sigma-Aldrich, Inc.,
Germany) diluted at 1/5000 in PBS containing 0.1% Tween-20
(PBS-T), the second under non-reducing conditions using the
anti-T. gondii SAG1 Mab (Product No. 11-132, Argene SA,
Verniolle; France) diluted at 1/1000 in PBS-T. Both blots were
then incubated with alkaline phosphatase-conjugated anti-
mouse Fc specific antibody produced in goat (Product No.
A7434 Sigma-Aldrich, Inc., Germany). The immune complex
was detected by BCIP/NBT AP substrate buffer (100 mM Tris–
HCl pH 9.5, 100 mMNaCl, 5 mMMgCl2, containing 0.3 g/l NBT
and 0.15 g/l BCIP) and the reaction was stopped by washing
with distilled water.2.5. Protein quantiﬁcation
For estimating the amounts of the recombinant fusion
protein contained in periplasmic extract, SAG1–AP protein
levels were quantified on silver-staining SDS-PAGE using
Quantity-One Software (version 4.6.3, Bio-Rad, USA) with
bovine serum albumin as standard.2.6. Functional tests of the SAG1–AP fusion protein
2.6.1. Protein immunoblot assay under native conditions
The non-reducing and non-denaturing environment of
native PAGE allows the detection of biological activity.
Periplasmic extracts containing the recombinant fusion
protein was separated using 10% native PAGE gel. Then
Western blot was performed to reveal the AP activity using
directly BCIP/NBT AP substrate buffer (100 mM Tris–HCl
pH 9.5, 100 mM NaCl, 5 mM MgCl2, containing 0.3 g/l NBT
and 0.15 g/l BCIP) onto nitrocellulose membrane.2.6.2. Quantiﬁcation of AP-linked activity
Alkaline phosphatase activity was determined using a
biochemical colorimetric test. Briefly, increasing concentra-
tions of SAG1–AP and free AP contained in induced and non-
induced periplasmic extracts respectively (20–1500 ng/ml)
were diluted in assay buffer (1 M diethanolamine, 0.5 mM
MgCl2 at pH 9.8) and incubated with 1 mg/ml pNPP AP
substrate (p-nitro-phenyl-phosphate; Sigma-Aldrich, Inc.), in
96-well ELISA plates. The enzymatic AP activity was assayed
by measuring the p-nitrophenol formed from the enzymatic
hydrolysis of p-nitro-phenyl-phosphate at 405 nm using a
microplate reader (Labsystems Multiskan EX, Finland). All
assays were conducted in duplicate. The specific activity was
calculated as A405 U/μg protein.2.6.3. Immunoreactivity and bi-functionality
Immunoreactivity and bi-functionality of the recombinant
SAG1–AP fusion protein were tested in anti-T. gondii SAG1
Mab based ELISA. Briefly, 96-well ELISA plates (Maxisorp,
Nunc, Roskilde, Denmark) were coated with 100 μl/well of
100 mM carbonate–bicarbonate buffer (pH 9.6) containing
5 μg/ml anti-SAG1 Mab and incubated overnight at 4 °C.
Blocking for non-specific binding was performed for 1 h at
37 °C with PBS-T and 5% skim milk powder. The activated
plates were incubated for 1 h at 37 °C with 100 μl of twofold
dilutions of periplasmic extract containing the SAG1–AP
conjugate starting from 1.5 μg/ml. Wells were then incubated
with 100 μl of AP substrate (1 mg/ml pNPP diluted in 1 M
diethanolamine buffer, pH 9.8, containing 0.5 mMMgCl2) for
30 min at 37 °C. The wells were washed three times with
PBS-T between each intermediate step. The absorbance at
405 nm (A405 nm) was measured using a microplate reader.
Background was determined by incubating the wells directly
with the non-induced periplasmic extract. All assays were
conducted in duplicate.2.6.4. Serological-based assays
2.6.4.1. Human sera samples. Sera samples were provided by
the “Laboratoire de Parasitologie Médicale, Institut Pasteur de
Tunis” and were collected from pregnant women for system-
atic toxoplasmosis screening during their first prenatal consul-
tation. The patient's immune status towards toxoplasmosis and
specific IgG titers for positive ones were established using the
standard ELISA Platelia™ Toxo IgG kit (Product No. 72840,
Bio-Rad, France).2.6.4.2. Direct-ELISA test. Sera samples from Toxoplasma sero-
positive and sero-negative patients were diluted 1/20 in
100 mM carbonate–bicarbonate buffer (pH 9.6) and then,
volumes of 100 μl/well were used to coat ELISA plates at 4 °C
overnight. After blocking with 5% skim milk in PBS-T, the
activated plates were incubated for 1 h at 37 °Cwith 100 μl/well
of periplasmic extract containing the recombinant SAG1–AP
conjugate. The intermediate washing steps with PBS-T and
developing were as described earlier using AP substrate.
Background was assessed by incubating the wells with the
non-induced periplasmic extract. All assays were conducted in
duplicate.
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immunoblotting protocol. Volumes of 10 μl of sera samples
from Toxoplasma sero-negative and sero-positive patients
were spotted onto nitrocellulose membrane, allowed to air
dry and then blocked with blotto. The membrane was
incubated for 1 h at room temperature with a periplasmic
preparation containing the SAG1–AP fusion protein. Specific
immunocomplexes were detected by incubation for 20 min
in the BCIP/NBT AP substrate buffer. The membrane was
washed three times with PBS-T between each step. Back-
ground was assessed in the same conditions with the
non-induced periplasmic extract.
3. Results
3.1. Cloning and expression of SAG1–AP fusion protein
According to the primers used, sag1 coding gene fragment
was PCR-amplified as 867 bp including SfiI/NotI clamp se-
quences (data not shown). After digestion with restriction
enzymes, DNA fragment was ligated into the SfiI/NotI cloning
site of the pLIP6-GN vector. The recombinant plasmid was
transformed into the E. coliDH5α strain; rapid visual screening
on BCIP containing agar plates allowed detection of recombi-
nant clones and the corresponding plasmids were sequenced.
As expected in all blue colonies, insertion of the sag1 gene
between codons +6 and +7 of AP gene restored the initial
frame of the AP gene in the vector. In the retained plasmid,
nucleotide and deduced amino acid sequences of sag1were in
agreement with GenBank database (accession no. X14080)
(data not shown).
The recombinant pLIP6-sag1–AP vector was subsequently
used to transform E. coli XL1-blue strain. The colonies were
grown in LB medium at 37 °C, and then induced with 0.5 mM
IPTG at 28 °C overnight. Periplasmic fusion protein was
extracted using cold osmotic shock. A protein band with anFig. 1. SAG1–AP fusion protein expression analysis and identification. SDS-PAGE ana
blots revealing the SAG1–AP fusion protein treated with anti-AP Mab (B), or anti-T. g
vector. After induction, periplasmic proteins were extracted by cold osmotic shock a
to non-induced cell culture (1), crude periplasmic preparation (2) and cytoplasmicapparent molecular weight of 78 kDa was detected after
SDS-PAGE on homogenous 10% silver staining gel (Fig. 1A,
lane 2), in agreement with the SAG1–AP predicted molecular
mass. This band was absent in the non-induced cell culture.
The identity and the integrity of this band as the SAG1–AP
conjugate were confirmed further by two Western blotting
after SDS-PAGE. The first was revealed with the anti-bacterial
AP MAb (Fig. 1B) and detected the 78 kDa-recombinant
protein in periplasmic and cytoplasmic fractions from induced
recombinant bacteria tested. The second blot was revealed
with the conformational anti-T. gondii SAG1 Mab (Fig. 1C) and
only the periplasmic SAG1–AP was detected. This means that
the intact SAG1–AP fusion proteinwas released in soluble form
into the bacterial periplasm, where the SAG1 antigen adopts a
native-like structure. No visible degradation products are
revealed using anti-SAG1, suggesting the stability of the fusion
protein. However, a band of 48 kDa molecular weight corre-
sponding approximately to the size of free AP was detected
with or without inducer (Fig. 1B) and its presence reflects the
background of expression as classically observed in the case of
the tac promoter. This observation has also been reported by
other groups (Mérienne et al, 1997).
Attempts to improve the periplasmic production of the
recombinant fusion protein have beenmade using E. coli XL-1
blue and W3110 strain in various conditions. Namely, for the
determination of the effect of IPTG concentration on the
production of SAG1–AP, cultures in LB medium were induced
with different IPTG concentrations (0.1, 0.25, 0.5, and
1.0 mM), then incubated overnight. TheWestern blot pattern
of periplasmic extracts from induced cultures showed the
presence of a 78 kDa band corresponding to the SAG1–AP
fusion protein in both E. coli strains (Fig. 2). Optimal production
was obtained in theW3110 strain with a 0.5 mM IPTG inducer
concentration. Typical 1L recombinant bacteria culture in
shaker flasks led to the production of about 1.5 mg recombi-
nant soluble SAG1–AP conjugates. This yielded enoughlysis of bacterial periplasmic extract after silver-staining (A) and twoWestern
ondii SAG1 Mab (C). E. coli XL-1 blue was transformed with the pLIP6-sag–AP
nd 5 μg of periplasmic proteins were applied in the gels. Numbers correspond
fraction (3). MW: molecular weight markers in kDa are indicated on the left.
Fig. 2. Effect of IPTG concentration on production of the SAG1–AP conjugate.
XL-1 blue and W3110 bacterial culture were induced at various IPTG
concentrations. The periplasmic extracts were analyzed by Western blotting
treated with anti-AP Mab. Volumes of 20 μl of protein samples were applied.
Columns 1, 2, 3 and 4 represent expression induction at 0.1, 0.25, 0.5, and
1.0 mM IPTG, respectively.
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of the recombinant protein and for an exploration of the
immunoreactivity of the fusion protein with human sera.
3.2. Biological activity of the hybrid protein
Recombinant fusion protein was assayed for both AP and
T. gondii SAG1 activities.
3.2.1. Evaluation of AP-linked activity
Periplasmic extracts obtained previously were blotted
onto nitrocellulose membrane under native PAGE condition
and the AP activity was directly revealed using BCIP/NBT AP
substrate (Fig. 3A, lane 2). The periplasmic protein bandsFig. 3. Evaluation of AP-linked activity. Panel A: Periplasmic extracts containing SAG1–A
conditions and directly revealed with BCIP/NBT AP substrate. Lane-1: non-induced
colorimetric assay of AP and SAG1–AP. Increasing concentrations of SAG1–AP (▲) an
96-well ELISA plates in assay buffer and incubated with pNPP AP substrate. The coloriwere stained by the AP substrate. This result first indicates
that the AP remains active within the fusion protein and
second that the whole periplasmic extract can be directly
used as a marker (Mousli et al., 2007; Muller et al., 2001).
Furthermore, AP activity was also determined using a bio-
chemical colorimetric test in ELISA plates, with successive
dilutions of crude periplasmic extracts in the presence of
soluble pNPP AP substrate. Optical densities (O.D) were
measured at 405 nm. SAG1–AP O.D values were calculated as
the difference between O.D measures obtained with the
induced and non-induced periplasmic extracts, respectively.
As shown in Figure 3B, the SAG1–AP conjugate displays an
enzymatic activity similar to that of free AP. This result is
consistent with data published by Butera and co-workers
(Butera et al., 2003). The specific activities were calculated as
18.5 OD405/μg to SAG1–AP and 21 OD405/μg to free AP.
3.2.2. Evaluation of bi-functionality of SAG1–AP conjugate by ELISA
We investigated the bi-functionality of the recombinant
fusion protein by ELISA using anti-T. gondii SAG1 Mab coated
plates. The bound conjugate was directly revealed by the AP
activity of the recombinant immunoconjugate preparation
(Fig. 4). The corresponding colorimetric signal increased in a
dose-dependent manner with increasing amounts of SAG1–
AP within the range tested. No significant background was
detectable when incubating the wells with the non-induced
periplasmic extract. The recombinant fusion protein holds
both the AP enzymatic activity and the SAG1 immunoreac-
tivity. This result strongly indicates that the recombinant
SAG1–AP conjugate is fully bi-functional.
3.2.3. Recombinant SAG1–AP conjugate-based immunoassays
Immunoreactivity of the recombinant SAG1–AP conjugate
with a collection of human sera samples, from T. gondii
sero-positive and sero-negative patients, was performed by
direct-ELISA and dot-blot assays. In the ELISA experiment, theP fusion proteinwere blotted onto nitrocellulosemembrane under native PAGE
cell culture and Lane-2: crude periplasmic preparation. Panel B: Biochemical
d AP (■) contained in periplasmic extracts (20–1500 ng/ml) were applied in
metric reaction was determined by measuring absorbance at 405 nm.
Fig. 4. ELISA assay to evaluate the bi-functionality of the SAG1–AP fusion
protein. 96-well ELISA plates were coated with anti-T. gondii SAG1 Mab and
treated with increasing concentrations of SAG1–AP (▲) contained in
periplasmic extracts (15–1500 ng/ml) in a one-step procedure. The AP-
linked activity was determined by measuring the absorbance at 405 nm
after incubation with AP substrate solution. The background was assessed
with the non-induced periplasmic extract (●).
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conjugate was able to directly detect specific anti-T. gondii
antibodies using the soluble chromogenic pNPP substrate
and discriminate between negative and positive samples
according to the standard gold test results (Fig. 5A). Low
background values were obtained for all sera (data not
shown) and deducted from final values. As seen in the ELISA
analysis, the dot-blot assay confirmed the SAG1–AP immuno-
detection of specific T. gondii antibodies (Fig. 5B). Positive
samples were clearly detected by visual inspection when the
assays were performed with sera samples having O.D values
over 0.5 by the SAG1–AP direct-ELISA. Under this value, the
dot-blot was considered as doubtful and discarded (data notFig. 5. Immunoreactivity of the SAG1–AP fusion protein with T. gondii antibodies in h
samples diluted at 1/20. After incubation with induced periplasmic extract contain
substrate solution. The absorbance was read at 405 nm. Panel B, dot-blot: Sera sam
incubated with SAG1–AP reagent and then, the dots were revealed with BCIP/NBT A
periplasmic extract and “NS” and “PS” refers to negative and positive sera samplesshown). No significant background staining was observed.
For both immunoassays, the total one-step reaction proce-
dure takes no more than 2 h to detect specific antibody
responses against T. gondii.
4. Discussion
In this study, for the first time, utility of the full length
recombinant SAG1 antigen genetically fused to bacterial
alkaline phosphatase in the serodiagnosis of human toxo-
plasmosis was examined. Therefore, we first described, the
successful production of the chimerical protein based on
alkaline phosphatase-fused to the T. gondii surface antigen 1
in the periplasmic space. Then, biological activities of the two
proteic partners were reported separately. Finally, the value
of the SAG1–AP fusion protein as a novel in vitro tool to
detect specific antibody responses against T. gondii in a
one-step procedure was established.
Although SAG1 was the most widely explored antigen and
has been shown to be a good candidate for Toxoplasma
diagnosis, its expression is very difficult to achieve in E. coli
systemsas it contains a proportionally high number of cysteines
(12 residues) assembling six intramolecular disulfide bonds
that give rise to immunologically relevant conformational
epitopes (Cesbron-Delauw et al., 1994). It has been reported
that full-sized recombinant SAG1 was essentially expressed in
E. coli as insoluble inclusion bodies form, requiring a time
consuming and expert process to recover activity through
in vitro refolding steps, to finally result in lowbinding to immune
sera (Aubert et al, 2000; Chen et al., 2001). Similarly, using a
truncated form of SAG1 may decrease the immunoreactivity of
the recombinant antigen and may be poorly recognized by the
antiserum against native SAG1. Consequently, in the present
study,we selected a gene fragment coding for thewhole T. gondii
SAG1 protein and expressed it in the pLIP system as fusion
antigen. This approach enabled the production of a soluble
and bi-functional fusion protein formed of a SAG1 antigenicuman sera samples. Panel A, direct-ELISA: Microplates were coated with sera
ing the SAG1–AP fusion protein, the immune complex was revealed with AP
ples were dotted onto nitrocellulose membrane. After blocking, strips were
P substrate. For both assays, background was assessed with the non-induced
, respectively.
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monomer. Indeed, our functional data strongly suggest that this
strategy of expression allows the correct assembly of the six
SAG1 disulfide bonds without hindrance to the formation of the
enzymatically active AP. The SAG1–AP specific catalytic activity
is similar to that of free AP, indicating that all the exported fusion
protein is properly folded. Moreover, since the bacterial AP is
only active as a homodimer (Martin et al., 1999), we anticipate
that the produced SAG1–AP component has a divalent form.
The SAG1–AP protein generated with the gene fusion
approach represents a better alternative methodology to the
conventional chemical immunoconjugates cross-linking, avail-
able for use as a secondary reagent, which lead to conjugates
with highly reduced activity even under mild condition (van
Loon et al., 1983; Lindenschmidt, 1986; Jablonski, 1985). In
addition, the genetic procedure of production is simple,
reproducible and offers the possibility to store bacterial cells
indefinitely. Furthermore, production can be adapted to an
industrial scale and the engineered chimerical bi-functional
molecule could be purified in one-step using immunoaffinity
purification systems.
At the moment, the produced amounts were sufficient to
investigate the recombinant conjugate value as a novel tool for
T. gondii serodiagnosis. For that, direct-ELISA and dot-blot
immunoassays, based on recombinant SAG1–AP, were devel-
oped to detect anti-T. gondii specific antibodies in human sera
samples from positive patients versus a control group. Here, the
crude periplasmic extract containing the SAG1–AP conjugate
was directly applied on sera samples and demonstrated that it
can be effectively used as a marker, since it discriminated well
between T. gondii immune and non-immune individuals and
displayed a very low background. Thus, the proposed sero-
diagnosis tests for Toxoplasma antibodies detection are direct,
rapid and offer various possibilities. In fact, the fully bi-
functional SAG1–AP fusion protein makes possible single-
step immunoassay which does not require a secondary
immunoconjugate. Moreover, direct-ELISA and dot-blot assays
are qualitative methods that detected specific anti-T. gondii
immunoglobulins in sera from sero-positive patients by visual
inspection. Nevertheless, we can enhance the visual detection
of positive samples versus negative ones, by means of an
optimized immunodetection process. Firstly, purification of the
recombinant SAG1–AP reagent can be processed for a better
calibration of the assay and to by-pass the potential drawbacks
correlated to the use of crude periplasmic extracts. Secondly,
the sensitivity of detection in ELISAs can be improved through
the use of the recently developed alkaline phosphatase
chemiluminescent substrates (Dong et al., 2012). Thirdly,
direct coating of the serum components could probably
generate artifacts, especially if the antibodies of interest are
in low amounts as compared to other serum components.
Consequently, the proposed ELISA test could be advanta-
geously adapted by developing antibody capture immunoas-
says that (i) permit an oriented and homogeneous affinity-
capture of specific antibodies improving the signal detection and
(ii) allow the discrimination between primary and secondary
Toxoplasma infection phases, while detecting specific IgM
or IgG antibodies respectively, which is of utmost im-
portance in pregnant women. Under these conditions, no
sophisticated detection system is required suggesting that
these methods, based on the SAG1–AP conjugate, could beapplied to Toxoplasma screening, in large-scale epidemio-
logical surveys especially under field conditions.
Therefore, the recombinant SAG1–AP conjugate seems to
be a promising tool for Toxoplasma serodiagnosis and thanks
to the SAG1 dimeric display, stability of the SAG1/anti-T.
gondii antibody interaction could be increased, especially
when examining low affinity interactions. However, addi-
tional evaluation on a larger series should be performed to
confirm the reliability, reproducibility and performances of
the direct-ELISA and rapid dot-blot tests to detect specific
Toxoplasma antibodies. Furthermore, the recombinant color-
imetric SAG1–AP could provide the basis for direct antibody
capture enzyme-immunoassay for specific immunoglobulin
M and G detection.
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